News >

Immunotherapy's Role in TNBC May Be in Combination

Angelica Welch
Published: Tuesday, Apr 24, 2018

Hatem Soliman, MD

Hatem Soliman, MD
Immunotherapy has had a challenging journey breaking through the breast cancer treatment landscape. Recently, responses have been seen in some patients with triple-negative breast cancer (TNBC), signaling a potential role for immunotherapy in this tumor type.

TNBC is a heterogeneous group of breast cancer that is made up of several subtypes. It is traditionally defined as breast cancer with <1% staining of estrogen receptor and progesterone receptor, and it is negative for amplification or overexpression of HER2.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication